• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Otonomy Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    3/28/23 9:16:02 AM ET
    $OTIC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $OTIC alert in real time by email
    8-K
    NONE false 0001493566 0001493566 2023-03-24 2023-03-24 0001493566 dei:FormerAddressMember 2023-03-24 2023-03-24

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of The Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported):

    March 24, 2023

     

     

    Otonomy, Inc.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   001-36591   26-2590070

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

     

    Address Not Applicable1   Address Not Available
    (Address of principal executive offices)   (Zip Code)

    (619) 488-6202

    (Registrant’s telephone number, including area code)

    4796 Executive Drive

    San Diego, California 92121

    (Former name or former address, if changed since last report.)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading

    Symbol(s)

     

    Name of each exchange

    on which registered

    Common stock, par value $0.001 per share   OTIC   OTC Pink

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company  ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

     

    1 

    Otonomy, Inc. (the “Company”) terminated its lease agreement for office space. Accordingly, the Company does not maintain a headquarters. For purposes of compliance with applicable requirements of the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended, any communication required to be sent to the Company’s principal executive offices may be directed to the Company’s agent for service of process at Corporation Service Company, 251 Little Falls Drive, Wilmington, New Castle County, Delaware 19808, or to the email address set forth in the Company’s investor relations website.

     

     

     


    Introductory Note

    This Current Report on Form 8-K is being filed in connection with the previously announced voluntary liquidation and dissolution of Otonomy, Inc. (the “Company”) under the General Corporation Law of the State of Delaware (the “Dissolution”). On March 24, 2023, the stockholders of the Company approved the Dissolution pursuant to the Plan of Liquidation and Dissolution of the Company (the “Plan of Dissolution”). The information in this Current Report on Form 8-K supplements and supersedes the prior disclosures of the Company.

     

    Item 3.03.

    Material Modifications to the Rights of Security Holders.

    On March 28, 2023, the Company filed a certificate of dissolution (the “Certificate of Dissolution”) with the Secretary of State of the State of Delaware. A copy of the Certificate of Dissolution and the Plan of Dissolution are filed herewith as exhibits 4.1 and 99.1, respectively, and are incorporated herein by reference.

    In accordance with the Plan of Dissolution, the Company has instructed its transfer agent to close the Company’s stock transfer books and discontinue recording transfers of the Company’s common stock (the “Common Stock”) effective as of 4:00 p.m., Eastern time, on March 28, 2023 (such time and date, the “Record Date”), and to notify DTC of the same. The Common Stock and stock certificates, if any, evidencing the shares of Common Stock, will no longer be assignable or transferable on the Company’s books as of the Record Date, other than transfers by will, intestate succession or operation of law. Additionally, on March 24, 2023, the Company’s board of directors (the “Board”) approved a liquidating distribution of $0.11 per share in cash to the Company’s stockholders of record as of the Record Date. The Company expects to pay such liquidating distribution promptly. In the future, and pursuant to the Plan of Dissolution, the Company may distribute up to an additional $0.02 per share in cash to the Company’s stockholders of record as of the Record Date if the Board determines that the amounts previously reserved by the Company no longer need to be reserved.

    In connection with the Dissolution, the Company also notified FINRA of its intent to close the stock transfer books of the Company on the Record Date. The Company previously delisted from The Nasdaq Global Select Market, and a Form 25 in respect of such delisting was filed with the Securities and Exchange Commission on December 29, 2022.

     

    Item 5.02.

    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

    On March 24, 2023, in connection with the Dissolution, Paul E. Cayer informed the Company that he will step down as President, Secretary and Chief Financial and Business Officer of the Company, effective as of the close of business on March 31, 2023. Mr. Cayer will also no longer serve as a consultant of the Company after that time. The Board appointed David Maggio, a representative of Armanino LLP (“Armanino”), a consultant to the Company, as President and Secretary of the Company, effective as of the departure of Mr. Cayer. The Company pays consulting fees to Armanino, but Mr. Maggio will receive no compensation for his role as an officer of the Company.

     

    Item 5.07.

    Submission of Matters to a Vote of Security Holders.

    On March 24, 2023, the Company held a special meeting of stockholders (the “Special Meeting”) virtually via live webcast. As of the close of business on February 3, 2023, the record date of the Special Meeting, there were 68,527,264 shares of Common Stock issued, outstanding and eligible to vote at the Special Meeting.

    Stockholders of the Company who collectively held 39,846,520 shares of Common Stock, or 58.14% of the Common Stock entitled to vote, were present at the Special Meeting in person or by proxy and constituted a quorum. Stockholders of the Company voted on and approved the following two proposals, with the final results included below:

    Proposal 1: To approve the Dissolution of the Company pursuant to the Plan of Dissolution (the “Dissolution Proposal”).

     

    For

     

    Against

     

    Abstain

     

    Broker Non-Votes

    38,342,139   1,397,065   107,316   Not Applicable

    The Dissolution Proposal was approved.


    Proposal 2: To grant discretionary authority to the Board to adjourn the Special Meeting, from time to time, to a later date or dates, even if a quorum is present, to solicit additional proxies in the event that there are insufficient shares present in person (including virtually) or by proxy voting in favor of the Dissolution Proposal (the “Adjournment Proposal”).

     

    For

     

    Against

     

    Abstain

     

    Broker Non-Votes

    38,155,169   1,301,461   389,890   Not Applicable

    The Adjournment Proposal was approved. As a result of the approval of the Dissolution Proposal, the Board did not exercise its discretionary authority pursuant to the Adjournment Proposal.

     

    Item 9.01.

    Financial Statements and Exhibits.

    (d) Exhibits

     

    Item
        No.    

      

    Description

      4.1    Certificate of Dissolution, as filed by Otonomy, Inc. with the Secretary of State of the State of Delaware, effective March 28, 2023
    99.1    Plan of Liquidation and Dissolution of Otonomy, Inc.
    104    Cover Page Interactive Data File (embedded within the Inline XBRL document)


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

     

          OTONOMY, INC.
    Date: March 28, 2023     By:  

    /s/ Paul E. Cayer

          Paul E. Cayer
          President, Secretary and Chief Financial and Business Officer
    Get the next $OTIC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OTIC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $OTIC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Hogan H Michael Iii

    3 - OTONOMY, INC. (0001493566) (Issuer)

    2/24/23 4:53:45 PM ET
    $OTIC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4: Weber David Allen covered exercise/tax liability with 91,636 shares, decreasing direct ownership by 24% to 285,863 units (withholding obligation)

    4 - OTONOMY, INC. (0001493566) (Issuer)

    12/30/22 4:31:39 PM ET
    $OTIC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4: Cayer Paul E covered exercise/tax liability with 40,054 shares, decreasing direct ownership by 18% to 183,733 units (withholding obligation)

    4 - OTONOMY, INC. (0001493566) (Issuer)

    12/30/22 4:30:19 PM ET
    $OTIC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OTIC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Otonomy Announces Change in Stock Exchange Listing

    SAN DIEGO, Dec. 22, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC) today announced that it received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (Nasdaq) indicating that the company's shares would be suspended from trading on Nasdaq effective at the open of business on December 23, 2022. Following such suspension, the company's shares will be traded on the OTC Pink Market. As previously reported, on November 14, 2022, Otonomy received a notice from Nasdaq indicating that the Listing Qualifications Staff (the Staff) had determined to delist the company's securities unless the company timely requested a hearing before the Nasdaq Hearings Panel (the Pan

    12/22/22 7:53:14 AM ET
    $OTIC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Otonomy Provides Corporate Update

    SAN DIEGO, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC) today announced that the company's board of directors, after considering strategic options, has approved and adopted a Plan of Liquidation and Dissolution ("Plan of Dissolution") that would include the distribution of remaining cash to stockholders following an orderly wind down of the company's operations, including the proceeds from the sale of any pipeline assets. To reduce cost, Otonomy has implemented a reduction in workforce. These updates are discussed below. Evaluation of Strategic Options As previously reported, Otonomy initiated an evaluation of strategic options to realize value from its pipeline. The

    12/19/22 4:53:38 PM ET
    $OTIC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Otonomy Reports Third Quarter 2022 Financial Results and Provides Corporate Update

    SAN DIEGO, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today reported financial results for the quarter ended September 30, 2022 and provided an update on its product pipeline and corporate activities. Otonomy Program and Corporate Activity Updates In August 2022, Otonomy announced that OTO-313 demonstrated no clinically meaningful improvement versus placebo for primary and secondary endpoints in a Phase 2 clinical trial in tinnitus patients. Based on these results, Otonomy discontinued development of OTO-313 and implemented other measures to extend its cash runway. Th

    11/10/22 4:05:00 PM ET
    $OTIC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OTIC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    HC Wainwright reiterated coverage on Otonomy with a new price target

    HC Wainwright reiterated coverage of Otonomy with a rating of Buy and set a new price target of $5.50 from $10.00 previously

    3/1/21 8:38:28 AM ET
    $OTIC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HC Wainwright & Co. reiterated coverage on Otonomy with a new price target

    HC Wainwright & Co. reiterated coverage of Otonomy with a rating of Buy and set a new price target of $5.50 from $10.00 previously

    2/23/21 6:53:19 AM ET
    $OTIC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Piper Sandler reiterated coverage on Otonomy with a new price target

    Piper Sandler reiterated coverage of Otonomy with a rating of and set a new price target of $5.00 from $10.00 previously

    2/22/21 3:01:01 PM ET
    $OTIC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OTIC
    Leadership Updates

    Live Leadership Updates

    View All

    Otonomy Appoints Jill Broadfoot to Board of Directors

    SAN DIEGO, Aug. 19, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the appointment of Jill Broadfoot to its board of directors. "Jill is an excellent addition to the board with strong strategic, operational and financial expertise within the biopharmaceutical sector," said David A. Weber, Ph.D., president and CEO of Otonomy. "We are excited to welcome her as we continue our growth trajectory and make progress to achieving our clinical milestones." Since 2018, Ms. Broadfoot has served as chief financial officer (CFO) of aTyr Pharma, Inc., a biotherapeutics company. P

    8/19/21 7:30:00 AM ET
    $OTIC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OTIC
    Financials

    Live finance-specific insights

    View All

    Otonomy Reports Second Quarter 2022 Financial Results and Provides Corporate Update

    Top-line results for OTO-313 Phase 2 trial in tinnitus expected in August 2022; patient enrollment completed for clinical safety evaluation of higher and bilateral dosing of OTO-313 with top-line results expected in third quarter of 2022Positive top-line results announced for OTO-413 Phase 2a in hearing loss; enrollment completed for higher dose evaluation with top-line results expected in fourth quarter of 2022OTO-825 IND-enabling activities ongoing with IND filing expected first half of 2023Current capital funds operations through multiple clinical readouts Conference call and webcast today at 4:30 p.m. ET SAN DIEGO, July 25, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biop

    7/25/22 4:05:00 PM ET
    $OTIC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Otonomy to Report Second Quarter 2022 Financial Results and Provide Corporate Update

    SAN DIEGO, July 18, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will report financial results for the second quarter 2022 and provide a corporate update at 4:30 p.m. ET on July 25, 2022.  A live webcast of the call will be available online in the investor relations section of Otonomy's website at www.otonomy.com and will be archived there for 30 days. To access the live call by phone, please go to this link (registration link), and you will be provided with dial-in details. To avoid delays, we encourage participants to dial into the conference call fifteen minu

    7/18/22 7:30:00 AM ET
    $OTIC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Otonomy Reports First Quarter 2022 Financial Results and Provides Corporate Update

    Positive top-line results announced for OTO-413 Phase 2a in hearing loss; enrollment ongoing for higher dose evaluationOTO-313 Phase 2 trial in tinnitus fully enrolled with top-line results expected in August 2022; clinical safety evaluation of higher and bilateral dosing ongoingOTO-825 IND-enabling activities ongoing with IND filing expected first half of 2023Current capital funds operations through multiple clinical readouts and into second half of 2023 Conference call and webcast today at 4:30 p.m. ET SAN DIEGO, May 09, 2022 (GLOBE NEWSWIRE) --  Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today repor

    5/9/22 4:04:00 PM ET
    $OTIC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OTIC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Otonomy Inc. (Amendment)

    SC 13G/A - OTONOMY, INC. (0001493566) (Subject)

    2/14/23 4:06:58 PM ET
    $OTIC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Otonomy Inc. (Amendment)

    SC 13G/A - OTONOMY, INC. (0001493566) (Subject)

    2/13/23 8:49:22 AM ET
    $OTIC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Otonomy Inc. (Amendment)

    SC 13G/A - OTONOMY, INC. (0001493566) (Subject)

    2/10/23 4:29:37 PM ET
    $OTIC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OTIC
    SEC Filings

    View All

    SEC Form 15-12G filed by Otonomy Inc.

    15-12G - OTONOMY, INC. (0001493566) (Filer)

    4/4/23 3:40:49 PM ET
    $OTIC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by Otonomy Inc.

    EFFECT - OTONOMY, INC. (0001493566) (Filer)

    4/3/23 12:15:10 AM ET
    $OTIC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by Otonomy Inc.

    EFFECT - OTONOMY, INC. (0001493566) (Filer)

    4/3/23 12:15:09 AM ET
    $OTIC
    Biotechnology: Pharmaceutical Preparations
    Health Care